Cotinga Pharmaceuticals Inc. (COTQF)
OTC PINK OTC PINK Primary Summary
Cotinga Pharmaceuticals Inc. Profile
| - Industry | - Sector | Dr. Richard T. Ho CEO | OTC PINK Exchange | CA22164W1059 ISIN |
| CA Country | - Employees | - Last Dividend | 30 Jun 2017 Last Split | - IPO Date |
Overview
Cotinga Pharmaceuticals Inc. is a dynamic, clinical-stage biopharmaceutical company focusing on the development of novel therapies aimed at treating cancer and addressing other significant unmet medical needs. As a specialized entity in the healthcare sector, Cotinga stands out for its dedication to pioneering research in oncology and beyond. Notably, the company has a rich history of innovation and strategic collaborations, exemplified by its partnership with St. Vincent's University Hospital to explore the effectiveness of its prominent compound, COTI-2, in combination treatments. Originally operating under the name Critical Outcome Technologies Inc., the organization underwent a strategic rebranding to Cotinga Pharmaceuticals Inc. in January 2018, signifying a new phase in its commitment to combating cancer. Based in Toronto, Canada, Cotinga Pharmaceuticals leverages the vibrant scientific community within the region to advance its research and development efforts.
Products and Services
- COTI-2
An innovative oral small molecule, COTI-2 is at the forefront of Cotinga Pharmaceuticals’ pipeline, designed to target the p53 tumor suppressor gene. Recognized for its potential in oncology, this lead compound specifically targets one of the most prevalent pathways in cancer cell development and survival. With p53 being a critical component in the cell cycle and apoptosis regulation, COTI-2 presents a promising approach to inhibiting cancer growth by reactivating the tumor suppression activities of p53.
- COTI-219
COTI-219, another cornerstone of Cotinga’s innovative portfolio, is an oral small molecule aimed at targeting KRAS mutations. Distinctly designed to differentiate between mutant and normal forms of KRAS, COTI-219 offers a tailored approach to treating cancers driven by KRAS mutations without affecting the usual functions of KRAS. This specificity could significantly minimize potential side effects and improve treatment outcomes for patients with KRAS-mutant cancers.
